Here's Why Agenus Rose as Much as 23.3% Today
Shares of Agenus (NASDAQ: AGEN) jumped over 23% today after the company announced a presentation at the American Society of Clinical Oncology (ASCO) meeting discussing the progress of AGEN1181 in solid-tumor cancers.
The drug candidate delivered clinical benefit in 70% of patients with advanced tumors in the small-scale study, both as a monotherapy and in combination with another drug candidate from the company. If the results can hold up in larger clinical trials, AGEN1181 might have broad potential to improve outcomes for patients with a wide array of solid tumor cancers.
Investors have decided to price in some of that potential today. As of 12:39 p.m. EDT, the small-cap stock had settled to a 17.4% gain.
Source Fool.com
